| Luna Family Hearing | |
|
11516 Se Mill Plain Blvd, Suite J-2, Vancouver, WA 98684-5005 | |
| (360) 882-8027 | |
| (360) 882-8030 |
| Full Name | Luna Family Hearing |
|---|---|
| Type | Facility |
| Speciality | Audiologist-hearing Aid Fitter |
| Location | 11516 Se Mill Plain Blvd, Vancouver, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306156542 | NPI | - | NPPES |
| 2011076 | Medicaid | WA |
| Mailing Address | Practice Location Address |
|---|---|
| Luna Family Hearing Po Box 350, Maple Valley, WA 98038-0350 Ph: (425) 358-0956 | Luna Family Hearing 11516 Se Mill Plain Blvd, Suite J-2, Vancouver, WA 98684-5005 Ph: (360) 882-8027 |
News Archive
Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.
Researchers from the University of Miami and Harvard University address the challenges of effective universal health coverage in low- and middle-income countries, focusing on solving one of the most pressing issues: the care of chronic illnesses. Their suggestions, aimed at strengthening health care systems, include recommendations based on a "diagonal approach" for managing health care.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2010.
Menopausal hormone therapy (MHT), consisting of oral estrogen plus progestin or estrogen alone, considered in the past as treatment for urinary incontinenc, was until recently, credited with many benefits well beyond the indications for symptomatic relief of hot flashes, night sweats, and vaginal dryness. One of the benefits of MHT was to improve the symptoms of urinary incontinence (UI), and it has often been prescribed to treat UI.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections.
› Verified 4 days ago